目的 基于 CiteSpace 6.2.R6 对“中药治疗高尿酸血症肾病”的中文及英文文献进行文献计量学及可视化分析，探讨中药治疗高尿酸血症肾病的研究现状及趋势，为将来的基础研究和临床研究提供参考。方法 以中国学术期刊全文数据库（CNKI）、万方数据知识服务平台（Wanfang）、维普中文科技期刊数据库（VIP）作为中药治疗高尿酸血症肾病的中文文献的检索平台，英文文献以 Web of Science（WOS）为检索平台，不限制文献发表时间。应用 CiteSpace 6.2.R6 版软件对文献作者和机构进行合作分析，对关键词进行共现分析，以此提取可靠信息。结果 通过检索共得到 395 篇中文和 48 篇英文文献，可视化分析结果显示中英文文献发文量整体呈上升趋势，但是年均发文量表明中药治疗高尿酸血症肾病的研究并不多。作者合作网络分析显示作者之间存在交流合作，但是较为分散，合作不够密切，该领域主要由国内学者进行研究，机构间合作相对独立，主要单位为国内中医药大学及其当地医院，缺乏跨省交流，更没有跨国合作。关键词共现分析表明高尿酸血症肾病的直接作用器官为肾脏，中药同高尿酸血症肾病联系比较密切，提示了中药治疗高尿酸血症肾病的更多方向和可能。中文关键词聚类分析表明该项研究多集中于临床层次，缺乏基础性研究。英文关键词聚类展示了与中药治疗高尿酸血症肾病相关性比较大的两种分子，分别是白细胞介素-1（IL-1）和核苷酸结合寡聚化结构域样受体含 pyrin 结构域蛋白3（NLRP3）。分析总结出该研究未来趋势更趋向于先应用生物医药大数据来探寻中药同高尿酸血症肾病的相关联系，在此基础上进行深入研究，这也反映该项研究正处于发展阶段。结论 中药已经应用于高尿酸血症肾病的临床治疗中，对疾病起着一定作用，但是缺乏对其深入的基础性研究，因此限制了临床研究的发展。

Objective Based on CiteSpace 6.2. R6, to conducte bibliometric and visualization analyses of Chinese and English literature on traditional Chinese medicine for hyperuricemia nephropathy to understand the current status and trend of research on the treatment of hyperuricemia nephropathy by traditional Chinese medicine, and to provide references for future basic research and clinical research. Methods China Knowledge Network Database (CNKI), Wanfang Data Knowledge Service Platform (Wanfang), and Vip. com (VIP) were used as the search platforms for the Chinese literature on Chinese medicines for hyperuricemia nephropathy, and Web of science (WOS) was used as the search platform for the English literature, with no restriction on the publication time of the literature. And CiteSpace version 6.2. R6 software was applied to analyze the collaboration of literature authors and institutions, and to analyze the co-occurrence of keywords as a way to extract reliable information. Results A total of 395 Chinese and 48 English documents were obtained through the search, and the results of the visualization analysis showed that the number of Chinese and English literature publications showed an overall increasing trend, but the average annual number of publications indicated that there were not many studies on the treatment of hyperuricemia nephropathy with traditional Chinese medicine. The analysis of authors' cooperation network showed that there was communication and cooperation among authors, but it was more scattered and the cooperation was not close enough. This field was mainly researched by domestic authors, and the interinstitutional cooperation was relatively independent, with the main units being the domestic universities of traditional Chinese medicine and their local hospitals, and there was a lack of inter-provincial communication, not to mention transnational cooperation. Keyword co-occurrence analysis indicated that the direct organ of action of hyperuricemia nephropathy was the kidney, and that traditional Chinese medicine was more closely associated with hyperuricemia nephropathy, suggesting more directions and possibilities for the treatment of hyperuricemia nephropathy with traditional Chinese medicine. The keyword clustering analysis in Chinese showed that the study was mostly focused on the clinical level and lacked basic research. The keyword clustering analysis in English showed two molecules that were more relevant to the treatment of hyperuricemia nephropathy with traditional Chinese medicine, which were interleukin-1 (IL-1) and NLRP3. The analysis summarized that the future trend of this study was to apply the big data of biomedicine to explore the connection between traditional Chinese medicine and hyperuricemia nephropathy, and then carried out in-depth research on the basis of it, which was also a reflection of the developmental stage of this study. This also indicated that the study was in the development stage. Conclusion Traditional Chinese medicine has been used in clinical research on hyperuricemia nephropathy and plays a role in the disease, but lacks in-depth basic research, thus limiting the development of clinical research.

国家自然科学基金面上项目（82301725）；中国博士后科学基金第 73 批面上资助项目（2023M732155）；山西省基础研究计划面上 项 目（202203021212028）；山 西 省 高 等 学 校 科 技 创 新 项 目（2022L132）；山 西 省 卫 生 健 康 委 中 医 药 科 研 项目（2023ZYYC2034）；山西省科技厅基础研究项目（20210302124586）；山西省应用基础研究计划（201901D211573）；太原市科技局“双百攻关行动”首批关键核心技术攻关“揭榜挂帅”项目（2024TYJB0150）